245 filings
Page 8 of 13
424B3
rdie2
7 Nov 22
Prospectus supplement
6:26pm
DEFA14A
1n6km74a cwzs88kk7ib
7 Nov 22
Additional proxy soliciting materials
6:21pm
8-K
z5kni8j0cu
7 Nov 22
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
6:21pm
8-K
3qgt sngcf
14 Oct 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:25pm
8-K
684c8fw za9n872de74
11 Oct 22
Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
4:15pm
424B3
r02rlk w13mehn1r
7 Oct 22
Prospectus supplement
5:18pm
424B3
7g7w7kyb32xgg1mzk ay
30 Sep 22
Prospectus supplement
4:52pm
8-K
gxcmhu giak49s
30 Sep 22
Entry into a Material Definitive Agreement
4:49pm
DEFA14A
g50y2
26 Sep 22
Additional proxy soliciting materials
4:36pm
424B3
8usp 66nh
26 Sep 22
Prospectus supplement
4:34pm
8-K
ex8 g6s6mh
26 Sep 22
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors
4:30pm
DEFA14A
b00g45xg22i60
19 Sep 22
Additional proxy soliciting materials
5:00pm
DEF 14A
iv4vec7x w7ua7fr9
19 Sep 22
Definitive proxy
4:34pm
8-K
ev1q0 70q
12 Sep 22
Allarity Therapeutics Announces Appointment of New Auditor
4:10pm
PRE 14A
m9h5ygw
8 Sep 22
Preliminary proxy
5:00pm
6-K
ir7jradq wb0rqkr2
31 Aug 22
Report of Foreign Private Issuer
11:56am
8-K
zolt6cpm7s
29 Aug 22
Regulation FD Disclosure
6:30am
8-K
ktkgszph b6tb
26 Aug 22
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance
4:37pm
8-K/A
qi2y2
24 Aug 22
Changes in Registrant's Certifying Accountant
5:15pm